27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology

Science

Volumn 342, Issue 6162, 2013, Pages 1094-1098

  Nelson, Erik R ^a   Wardell, Suzanne E ^a   Jasper, Jeff S ^a   Park, Sunghee ^a   Suchindran, Sunil ^b   Howe, Matthew K ^a   Carver, Nicole J ^a   Pillai, Ruchita V ^a   Sullivan, Patrick M ^a   Sondhi, Varun ^c   Umetani, Michihisa ^c   Geradts, Joseph ^a   McDonnell, Donald P ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; 27-HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CYP27A1 PROTEIN, HUMAN;

BIOCHEMISTRY; CANCER; CYTOCHROME; ENZYME ACTIVITY; ESTROGENIC COMPOUND; LIGAND; LIPID; METABOLITE; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG RESISTANCE; ESTROGEN ACTIVITY; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPOTHESIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST TUMOR; DISEASE MODEL; FEMALE; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHOLESTANETRIOL 26-MONOOXYGENASE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; HYPERCHOLESTEROLEMIA; LUNG NEOPLASMS; MICE; TUMOR CELLS, CULTURED;

EID: 84888791736     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1241908     Document Type: Article

References (27)

1. F. Bianchini, R. Kaaks, H. Vainio, Lancet Oncol. 3, 565-574 (2002).
2. I. Capasso et al., Cancer Biol. Ther. 10, 1240-1243 (2010).
3. A. G. Renehan, D. L. Roberts, C. Dive, Arch. Physiol. Biochem. 114, 71-83 (2008).
4. N. F. Boyd, V. McGuire, J. Natl. Cancer Inst. 82, 460-468 (1990).
5. M. Ferraroni et al., Int. J. Epidemiol. 22, 772-780 (1993).
6. C. M. Kitahara et al., J. Clin. Oncol. 29, 1592-1598 (2011).
7. K. Undela, V. Srikanth, D. Bansal, Breast Cancer Res. Treat. 135, 261-269 (2012).
8. T. P. Ahern et al., J. Natl. Cancer Inst. 103, 1461-1468 (2011).
9. S. F. Nielsen, B. G. Nordestgaard, S. E. Bojesen, N. Engl. J. Med. 367, 1792-1802 (2012).
10. K. K. Chan, A. M. Oza, L. L. Siu, Clin. Cancer Res. 9, 10-19 (2003).
11. J. G. Gerber et al., J. Acquir. Immune Defic. Syndr. 39, 307-312 (2005).
12. W. W. Wong, J. Dimitroulakos, M. D. Minden, L. Z. Penn, Leukemia 16, 508-519 (2002).
13. C. D. DuSell et al., Endocrinology 151, 3675-3685 (2010).
14. C. D. DuSell, M. Umetani, P. W. Shaul, D. J. Mangelsdorf, D. P. McDonnell, Mol. Endocrinol. 22, 65-77 (2008).
15. E. R. Nelson et al., Endocrinology 152, 4691-4705 (2011).
16. M. Umetani et al., Nat. Med. 13, 1185-1192 (2007).
17. Materials and methods are available as supplementary materials on Science Online.
18. C. E. Connor et al., Cancer Res. 61, 2917-2922 (2001).
19. C. T. Guy, R. D. Cardiff, W. J. Muller, Mol. Cell. Biol. 12, 954-961 (1992).
20. E. Y. Lin et al., Am. J. Pathol. 163, 2113-2126 (2003).
21. M. Hansson, E. Ellis, M. C. Hunt, G. Schmitz, A. Babiker, Biochim. Biophys. Acta 1593, 283-289 (2003).
22. A. Sica et al., Semin. Cancer Biol. 18, 349-355 (2008).
23. M. A. Lyons, A. J. Brown, Lipids 36, 701-711 (2001).
24. G. Llaverias et al., Am. J. Pathol. 178, 402-412 (2011).
25. N. Alikhani et al., Oncogene 32, 961-967 (2013).
26. R. Karuna et al., Atherosclerosis 214, 448-455 (2011).
27. P. M. Sullivan et al., J. Biol. Chem. 272, 17972-17980 (1997).